It is now established that homeopathic remedies interact with the genetic blueprint and increase the expression of many genes. These new findings have permitted the development of an advanced form of homeopathic DNA, the sequence-specific homeopathic DNA (SSHD) remedy system. The SSHD system takes advantage of a wide range of medical, scientific and genetic discoveries. These new SSHD remedies enable the practitioner to offer a wider range of health care benefits to the community.
Many homeopathic remedies do not contain any pharmacologically acting substances. Therefore they must improve the health status of an individual by interacting with the transcriptome (transcriptome refers to those of the 25,000 human genes that are expressed in any particular cell or tissue) and re-arranging the expression of various genes that encode proteins that drive those particular health benefits. This is an important consideration because, in the last few decades, the results of many scientific studies have increased our understanding of genes that promote symptom patterns of many diseases when their expression is sub-optimal.
Homeopathy and the Transcriptome.
In 1997, the idea that homeopathic remedies could interact with the transcriptome and re-arrange the expression of various genes began to be formerly addressed (1, 2). Since then, many studies have confirmed that homeopathic remedies do have the capacity to increase the expression of many genes, see Refs. 1-3 and within.
Scientific investigations (4) have discovered that individual remedies such as Condurango and Hydrastis canadensis have the capacity to re-arrange the expression of many genes, well over a hundred. From a health care standpoint, this is a very important discovery because it is now known that the human genome contains many genes that promote health and protect against disease.
The same scientists also found (4) that these remedies re-arrange the expression of a range of quite different genes by altering epigenetic characteristics of the genome. Therefore with a view to advancing homeopathy, it became important to develop a way of using homeopathic remedies to target specific health-promoting genes in a predictable way. This became possible due to the pioneering work of the homeopath Dr Jenaer in the late 1960s. As part of his seminal work (5), he confirmed that homeopathic DNA molecules with defined nucleotide sequences could be used to target and modulate the activity of various health-promoting genes (see below).
DNA has long been used to prepare homeopathic remedies. It is included in Materia Medicas compiled by practitioners such as Dr O.A Julian (6), Dr Jenaer (7) and others (8). It is also included in various Homeopathic Pharmacopoeias such as the Homeopathic Pharmacopoeia of the United States (HPUS). It is prepared from either the sperms of fish or the thymus of cattle. It is of unknown sequence and purity and contains DNA of foreign origin. From a qualitative standpoint, the precise reproducibility of homeopathic DNA remedies is impossible.
Following administration of homeopathic DNA, many health benefits have been recorded by practitioners such as Dr. Suvarna (9) and those above. These findings confirm that homeopathic DNA can target genes that encode proteins that resolve many symptoms associated with different forms of ill-health.
Homeopathic DNA remedy preparations have been subjected to the proving process by a number of practitioners such as Dr Jenaer, Dr Julian, Robbins and others. Because a wide range of symptoms of ill-health is induced by administration of homeopathic DNA preparations, as part of the proving process and aggravations, it follows that homeopathic DNA has the capacity to target many genes that, when expressed, promote many symptoms of the disease.
Based on the effects of administration of homeopathic DNA, it made sense to develop a way of adapting the use of homeopathic DNA to target only specific health-promoting genes. As outlined above, this breakthrough was achieved by the brilliant work of the homeopath Dr Jenaer, who, along with Dr Marichal, introduced the use of DNA molecules with known sequences into the emerging homeopathic practice of Micro-Immunotherapy.
Efficacy of SSHD remedies.
As part of their pioneering work, Drs. Jenaer and Marichal conducted a series of clinical studies which confirmed the efficacy of homeopathic remedies prepared from DNA molecules with precise sequences. Results of their clinical investigations paved the way for the development of the SSHD remedy system. The significance of Drs. Jenaer and Marichal’s findings have been acknowledged by the international scientific community because the application of DNA molecules with precise sequences in a homeopathic setting has been granted a Patent, see EP0670164B1. Furthermore, the use of DNA molecules with precise nucleotide sequences to prepare legitimate homeopathic remedies has been validated by the Medicines and Healthcare products Regulation Agency (MHRA) in the U.K., see HR 17491/0001.
Based on the recognition of Dr Jenaer and Marichal’s work, an extensive series of SSHD remedies has now been developed. The application of these new remedies is based on a wide range of important scientific discoveries that have come to light in recent years. The current range of SSHD remedies may be found at www.homeovitality.com
New properties of DNA used for the preparation of SSHD remedies.
All DNA molecules that are used to prepare SSHD remedies are in double-strand form. They are in the order of 400 base pairs in length. They are manufactured by the world-class molecular genetics laboratory, GenScript using the classical DNA synthesising technology, the polymerase chain reaction. Unlike homeopathic DNA, this method of preparation absolutely excludes the presence of any DNA molecules of foreign or viral origin. They are of precise sequence, length and concentration so that remedy preparations are standardised and completely reproducible. The sequence of each of the new SSHD molecules is determined by reference to the sequence of the targeted gene/s reported as a consequence of the Human Genome Project and other reputable scientific reports.
The new SSHD molecules are potentised and administered in an aqueous phase to take advantage of some recently discovered new properties of DNA. For example, scientists have found that double-strand DNA molecules have unusual interactive properties in that, in solution, they can communicate with and be attracted to other DNA molecules with the same sequence (10). When mechanically stimulated, they can also emit sequence-specific electromagnetic signals that can be recognised by DNA molecules with the same sequence (11). This DNA mediated signalling (11) cannot be measured when DNA solutions are diluted more than 1 in 1012 (equivalent to 6C). That is why the SSHD remedies are used specifically at a potency of 6C.
Over many years, seminal work by Goodman and colleagues has shown that gene expression can be readily up-regulated by the application of electromagnetic signalling (12).
Advantages of the SSHD remedy system.
Based on a large body of research, SSHD remedies are designed to be completely safe.
New genetic health care discoveries usually take between 10-20 years before they can be used to develop a new form of treatment, usually in the form of a drug. By contrast, the SSHD system is able to translate relevant discoveries into a safe treatment modality far more quickly.
Remedy selection criteria.
How are gene targets selected for inclusion in the SSHD remedy range?
There are a number of different ways in which genes can cause disease or promote symptoms of ill-health. Many disease symptoms are produced when a gene loses the ability to produce a sufficient amount of a normal protein, that is, the gene is not expressed sufficiently. Based on the pioneering work of Drs. Jenaer and Marichal as well as the results of extensive work by Khuda-Bukhsh and others (1-3), SSHD remedies have been developed to address symptom pictures that are generated when the expression of a particular gene is sub-optimal. The symptom pictures generated by reduced expression of particular genes have been accurately recorded due to many years of world-class scientific investigations.
On the other hand, many diseases are caused by inherited or acquired changes in the DNA sequence of a gene (usually referred to as a mutation). These mutations cause symptoms of ill-health due to the formation of a protein that does not work properly. There are no SSHD or indeed any homeopathic remedies that can resolve diseases caused by DNA mutations because they cannot alter the inherited sequence of DNA.
When are SSHD remedies prescribed?
SSHD remedies are prescribed partly on the basis of symptom patterns that are generated when the expression level of a particular gene is sub-optimal. They are also prescribed on the basis of the known functions of the genes that they have been designed to target.
Examples of SSHD remedies.
There are a number of reasons why the expression of a gene may be sub-optimal. For example, the expression of some genes declines with age. The expression of one of the most important health-promoting genes discovered thus far, KL, is one of them. Since its discovery, scientists have shown that the KL gene, which synthesises the hormone Klotho, plays a very important role in slowing down the ageing process (13). Scientists have shown in an animal model that reduced the activity of KL results in acceleration of the ageing of many organs, and in particular, skin deterioration and wrinkling (14). These features are completely reversed by up-regulation of KL (15)
More recently, Dr Witkowski and co-workers showed that reduced KL activity is associated with impaired immunity and increased susceptibility to the development of auto-immunity (16). These scientists demonstrated that KL plays an important role in stabilising CD4+ helper T lymphocytes, cells that promote and control the activity of the adaptive immune system. Thus, to protect against many diseases, everyone would benefit by taking the KL gene targeting SSHD remedy on a permanent basis, particularly as they age. There are a number of SSHD remedies, including Elastin in this category.
On the other hand, there are a number of remedies that are of benefit to everyone when taken on a permanent basis at all times. For example, the highly toxic amino acid homocysteine, made naturally by the body, when in high concentrations in the blood, increases susceptibility to the development of heart disease, atherosclerosis and many other disorders. Blood levels of homocysteine are elevated when the protein MTHFR is reduced (17, 18). Therefore, an SSHD remedy has been developed to target the MTHFR gene to help control serum levels of homocysteine. There are a number of SSHD remedies in this category including some that are designed to help people avoid excessive weight gain.
By contrast, other remedies are only required on a transient basis. For example, with the onset of asthma, prescription of two quite different remedies is warranted. One SSHD remedy is designed to target the IL-10 gene. IL-10 is an immune suppressant and has been shown to suppress immune components of allergy. In fact, the positive effects of asthma drugs such as triamcinolone and montelukast are considered to be due to their ability to increase IL-10 production (19).
On the other hand, a completely different non-inflammatory form of asthma has recently been discovered (20). Almost half of the asthma patients may suffer from this form of asthma. It is due to a reduction in the concentration of a protein called sphingolipid in the walls of the airways. When the amount of sphingolipid in airway cells is reduced, the walls of the airways contract resulting in the onset of a non-inflammatory form of asthma that is completely non-responsive to immunosuppressive therapy. Sphingolipid synthesis is augmented by the SPT gene. Therefore administration of the remedy that targets the SPT gene (STeP1) is warranted in patients who present with asthma which does not respond to the IL-10 targeting remedy. There are a number of SSHD remedies in this category.
The IL-10 targeting DNA molecule is also a part of another remedy that has been formulated to respond to those who suffer from allergic eczema. In recent years, research has revealed important insights into the pathogenesis of the most common form of dermatitis, atopic (allergic) eczema, also known as atopic dermatitis. It is now understood that genes that control skin integrity (FGN) and immune responsiveness, IL-10, play a critical role in the development of atopic eczema.
The gene FGN encodes a protein called filaggrin. Filaggrin binds to keratin intermediate filaments in the skin to form a protective waterproof layer on the surface of the skin that keeps out a wide range of substances that can be recognised by the immune system. Reduced activity of filaggrin results in the formation of holes in the skin, through which environmental substances such as pollens can readily penetrate, making it dry and often scaly (21). Once environmental substances have penetrated the skin, those people whose immune system is able to produce an allergic-type of immune response develop an abnormal type of antibody against these environmental substances called IgE in the same way that those with allergic asthma do. The interaction between environmental substances and their corresponding IgE antibodies in the skin leads to the development of a local inflammatory reaction causing atopic or allergic eczema/dermatitis. As indicated above, the protein produced by the gene IL-10 has been shown to suppress the production of IgE antibodies and inflammation (19).
Therefore, now that the two most important factors that are involved in the development of atopic eczema/dermatitis are known, the remedy Eczeban has been developed to target and support both the genes FGN and IL-10.
For many years, scientists have searched for genes that are involved in depression. Recently, scientists from Germany’s Max Planck Institute of Psychiatry made the exciting discovery that the gene SLC6A15 was linked to severe depression.
They found that expression of the SLC6A15 gene, which regulates the brain’s excitatory transmitter glutamate, was reduced in people who were severely depressed (22). Therefore, the SSHD remedy Depress Aid was developed to target this important gene in sufferers of depression.
There are many other SSHD remedies that have been developed to target different genes that give rise to illnesses when their expression is sub-optimal.
By visiting the website, www.homeovitality.com information about a unique science-based online Diploma course that exposes practitioners to the basic scientific principles of biochemistry, genetics, immunology and more that underpin the present-day delivery of homeopathy can be found.
- Khuda-Bukhsh, Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo. Com. Ther. Med. 5: 43. 1997.
- Khuda-Bukhsh. Current trends in high dilution research with particular reference to gene regulatory hypothesis. Nucleus. DOI 10.1007/s13237-014-0105-0
- Saha et al., Evidence in support of gene regulatory hypothesis: Gene expression profiling manifests homeopathy effect as more than placebo. Int J High Dilution Res 2013; 12:162-167
- Saha et al., Ultra-highly diluted plant extracts of Hydrastis canadensis and Marsdenia condurango induce epigenetic modifications and alter gene expression profiles in HeLa cells in vitro. J Integr Med. 2015;13(5) www.elsevier.com/locate/issn/20954964/. (doi: http://dx.doi.org/10.1016/S2095-4964(15)60201-1).
- Jenaer M. Utilisation des acides nucléiques en homéopathie, Revue Belge d’Homéopathie, n°3, 1969.
- Julian O.A. Protocole expérimental Cortico-Viscéral Pharamcodynamique ou Pathogénésie du DNA et RNA. Revue Belge d’Homéopathie, 1973 n°2, Vol 8, p:437-451.
- Jenaer M. Acquisitions récentes en Homéopathie et pathogénie des acides nucléiques. revue Belge d’Homéopathie, 1973 n°2, Vol. 8, p: 453-470.
- Riley D, Zagon A. Homeopathy-Clinical homeopathic use of RNA: evidence from two provings. . 2005 Jan 94(1): 6. 33
- Suvarna. Homeopathic remedy DNA. Homeopathic J. 4, 2011.
- Baldwin et al., DNA double helices recognize mutual sequence homology in a protein free environment. J. Phys. Chem. B., 4:112, 2008.
- Montagnier et al. Electromagnetic signals are produced by aqueous nanostructures derived from bacterial DNA sequences. Interdiscip. Sci. Comput. Life Sci. DOI:10.1007/s12539-009-0036-7. 2009.
- Goodman et al., Exposure of human cells to low-frequency electromagnetic fields results in quantitative changes in transcripts.Structure and Expression. 1009:216.1989.
- Rosenblatt & Kuro-O. Klotho, an aging suppressor gene. Horm. Res., 2007: 67;191.
- Kuro-o M et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997:390;45.
- Kurosu H et al. Suppression of aging in mice by the hormone Klotho. Science. 2005:309; 1829.
- Witkowski et al., Klotho- a common link in physiological and rheumatoid arthritis-related aging of human CD4+ lymphocytes. J. Immunol., 2007: 178; 771.
- El-Sammak et al., Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects. Int. J. Med. Sci. 2004: 1, 181.
- Stelmach et al., A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin. Exp. Allergy, 2002: 32; 264.
- Worgall et al., Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity . Sci Transl Med 5, 186,67, 2013.
- Kohli et al., The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron. 2011: 70; 252.